Goldsmith M A, Weiss A
Howard Hughes Medical Institute, Department of Medicine, University of California, San Francisco 94143.
Proc Natl Acad Sci U S A. 1987 Oct;84(19):6879-83. doi: 10.1073/pnas.84.19.6879.
We have developed an approach for deriving and characterizing antigen-receptor (CD3/Ti) signal-transduction mutants. This strategy combines receptor-mediated growth inhibition and fluorescence-activated cell sorting with the Ca2+-indicator indo-1. Despite the expression of structurally normal CD3/Ti complexes, one such mutant (J.CaM1) fails to exhibit inositolphospholipid metabolism or Ca2+ mobilization in response to anti-CD3 or anti-Ti monoclonal antibodies and fails to produce lymphokines in response to these antibodies. Surprisingly, anti-Ti antibody retains its effectiveness as a stimulus for the down-regulation of CD3/Ti surface expression. These cells remain responsive to AIF-4, at least one anti-CD3 antibody, and some combinations of nonagonist anti-Ti and anti-CD3 antibodies. The mutation in J.CaM1 appears to lie in a proximal component of the signal-transduction apparatus.
我们已开发出一种用于推导和表征抗原受体(CD3/Ti)信号转导突变体的方法。该策略将受体介导的生长抑制、荧光激活细胞分选与Ca2+指示剂indo-1相结合。尽管表达了结构正常的CD3/Ti复合物,但其中一个这样的突变体(J.CaM1)在响应抗CD3或抗Ti单克隆抗体时,未能表现出肌醇磷脂代谢或Ca2+动员,并且在响应这些抗体时未能产生淋巴因子。令人惊讶的是,抗Ti抗体作为CD3/Ti表面表达下调的刺激物仍保持其有效性。这些细胞对AIF-4、至少一种抗CD3抗体以及非激动剂抗Ti和抗CD3抗体的某些组合仍有反应。J.CaM1中的突变似乎位于信号转导装置的近端组件中。